C25023: Effectiveness and Safety for Re-treatment with Brentuximab-Vedotin (BV) in Patients with Relapsed/Refractory (R/R) CD30+ malignancies: a retrospective medical chart review study in Spain. The BELIEVE Study.

07/01/2022
10/09/2024
EU PAS number:
EUPAS44653
Study
Finalised
Documents
Study protocol
Initial protocol
English (4.5 MB - PDF) View document
Study results
Study results
English (1.17 MB - PDF) View document
Study report
Other information